"The Evaluation of Stimulant Withdrawal"

Anxiety Clinical Trial

— MARC  

Official title:

Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00442923
• Other study ID #: 1P50DA018165
• Secondary ID: 1P50DA018165
• Status: Withdrawn
• Phase: Phase 2
• Start date: July 1, 2007
• Est. completion date: June 30, 2011

Study information

• Verified date: January 2019
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 30, 2011
• Est. primary completion date: June 30, 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center

• Must meet the clinical definition for methamphetamine dependence

• Self-reported methamphetamine use within 10 days of entering the study

• Must be able to understand and sign the consent form

Exclusion Criteria:

• Dependent on any other drug except nicotine, caffeine, marijuana and alcohol

• Pregnant or nursing mothers

• Psychosis

• Dementia

• Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid)

• History of withdrawal seizures or delirium tremors

• Use of MAO inhibitors within the last two weeks

• Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal

Related Conditions & MeSH terms

• Anxiety
• Behavior, Addictive
• Recurrence
• Relapse
• Substance Addiction
• Substance-Related Disorders

Intervention

Drug:
• Coreg

Locations

Country	Name	City	State
United States	US Veterans Hospital	Portland	Oregon

Sponsors (2)

Lead Sponsor	Collaborator
Aaron J. Janowsky	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States,